Seres therapeutics to highlight vowst™ data at idweek

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) today announced multiple abstracts to be presented at idweek 2023 in boston, massachusetts (october 11-15, 2023), including two posters of post-hoc analyses from the ecospor iii and ecospor iv phase 3 trials, which supported the recent approval by the us food and drug administration (fda) of vowst as the first orally-administered microbiota-based therapeutic for the prevention of recurrent c. difficile infection (rcdi) i.
MCRB Ratings Summary
MCRB Quant Ranking